BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 26121347)

  • 1. Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study.
    Tolia V; Youssef NN; Gilger MA; Traxler B; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S24-30. PubMed ID: 26121347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study.
    Tolia V; Youssef NN; Gilger MA; Traxler B; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S24-30. PubMed ID: 26422095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study.
    Tolia V; Youssef NN; Gilger MA; Traxler B; Illueca M
    BMC Pediatr; 2010 Jun; 10():41. PubMed ID: 20540767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
    Tolia V; Gilger MA; Barker PN; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26121348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
    Tolia V; Gilger MA; Barker PN; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26422096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old.
    Tolia V; Gilger MA; Barker PN; Illueca M
    J Pediatr Gastroenterol Nutr; 2010 Nov; 51(5):593-8. PubMed ID: 20706150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
    Armstrong D; Paré P; Pericak D; Pyzyk M;
    Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.
    Devault KR; Johanson JF; Johnson DA; Liu S; Sostek MB
    Clin Gastroenterol Hepatol; 2006 Jul; 4(7):852-9. PubMed ID: 16682260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
    Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
    Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
    Castell DO; Kahrilas PJ; Richter JE; Vakil NB; Johnson DA; Zuckerman S; Skammer W; Levine JG
    Am J Gastroenterol; 2002 Mar; 97(3):575-83. PubMed ID: 11922549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis.
    Raghunath AS; Green JR; Edwards SJ
    Clin Ther; 2003 Jul; 25(7):2088-101. PubMed ID: 12946553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis.
    Baker R; Tsou VM; Tung J; Baker SS; Li H; Wang W; Rath N; Maguire MK; Comer GM
    Clin Pediatr (Phila); 2010 Sep; 49(9):852-65. PubMed ID: 20522615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and endoscopic evaluation of gastroesophageal reflux disease in patients successfully treated with esomeprazole.
    da Silva EP; Nader F; Quilici FA; Eisig JN; Zaterka S; Meneghelli U
    Arq Gastroenterol; 2003; 40(4):262-7. PubMed ID: 15264050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
    Sharma P; Johnson DA; Monyak JT; Illueca M
    Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Tolerability of Esomeprazole in Children With Gastroesophageal Reflux Disease.
    Gilger MA; Tolia V; Vandenplas Y; Youssef NN; Traxler B; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S16-23. PubMed ID: 26121345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study.
    Lim H; Park JK; Chung H; Lee SH; Park JM; Park JH; Kim GH; Shin SK; Hong SJ; Lee KJ; Park MI; Jung HK; Kim HS; Sung JK; Jeon SW; Choi SC; Moon JS; Kim N; Park JJ; Hong SH; Kim NY; Jung HY
    BMC Gastroenterol; 2023 Dec; 23(1):447. PubMed ID: 38110901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms of CYP2C19 and IL1B have no influence on esomeprazole treatment for mild erosive esophagitis.
    Hsu WH; Kuo FC; Hu HM; Hsu PI; Wu DC; Kuo CH
    Kaohsiung J Med Sci; 2015 May; 31(5):255-9. PubMed ID: 25910560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety.
    Vakil NB; Shaker R; Johnson DA; Kovacs T; Baerg RD; Hwang C; D'Amico D; Hamelin B
    Aliment Pharmacol Ther; 2001 Jul; 15(7):927-35. PubMed ID: 11421866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial.
    Tan VP; Wong WM; Cheung TK; Lai KC; Hung IF; Chan P; Pang R; Wong BC
    J Gastroenterol; 2011 Jul; 46(7):906-12. PubMed ID: 21538030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease.
    Fiedorek S; Tolia V; Gold BD; Huang B; Stolle J; Lee C; Gremse D
    J Pediatr Gastroenterol Nutr; 2005 Mar; 40(3):319-27. PubMed ID: 15735486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.